Hedge Fund - Rhenman & Partners Asset Management
Vertex Pharmaceuticals Inc / Ma (VRTX)
Holding History Records
| No. | Filing Period | Value | % of Portfolio | Number of Shares | Avg. Quarterly Share Price |
|---|---|---|---|---|---|
| 1 | 2025 - Q1 (2025-03-31) | $32,361,735 | 3.72% | 66,750 | $466.00 |
| 2 | 2024 - Q4 (2024-12-31) | $20,135,000 | 2.06% | 50,000 | $463.53 |
| 3 | 2024 - Q3 (2024-09-30) | $22,207,570 | 1.8% | 47,750 | $480.37 |
| 4 | 2024 - Q2 (2024-06-30) | $25,310,880 | 2.43% | 54,000 | $434.05 |
| 5 | 2024 - Q1 (2024-03-31) | $23,617,565 | 2.23% | 56,500 | $422.74 |
| 6 | 2023 - Q4 (2023-12-31) | $38,654,550 | 3.86% | 95,000 | $369.42 |
| 7 | 2023 - Q3 (2023-09-30) | $26,602,110 | 2.86% | 76,500 | $349.73 |
| 8 | 2023 - Q2 (2023-06-30) | $22,346,285 | 2.35% | 63,500 | $336.94 |
| 9 | 2023 - Q1 (2023-03-31) | $26,065,360 | 2.86% | 83,500 | $299.93 |
| 10 | 2022 - Q4 (2022-12-31) | $23,102,400 | 2.41% | 80,000 | $304.77 |
| 11 | 2022 - Q3 (2022-09-30) | $29,952,000 | 3.13% | 96,000 | $287.72 |
| 12 | 2022 - Q2 (2022-06-30) | $26,770,000 | 3.04% | 95,000 | $267.66 |
| 13 | 2022 - Q1 (2022-03-31) | $23,357,000 | 2.3% | 89,500 | $237.33 |
| 14 | 2021 - Q4 (2021-12-31) | $36,704,000 | 2.44% | 165,000 | $194.45 |
| 15 | 2021 - Q3 (2021-09-30) | $29,929,000 | 2.1% | 165,000 | $195.24 |
| 16 | 2021 - Q2 (2021-06-30) | $43,531,000 | 2.95% | 215,897 | $209.17 |
| 17 | 2021 - Q1 (2021-03-31) | $36,192,000 | 2.52% | 168,421 | $219.65 |
| 18 | 2020 - Q4 (2020-12-31) | $27,179,000 | 2.21% | 115,000 | $229.44 |
| 19 | 2020 - Q3 (2020-09-30) | $29,933,000 | 2.66% | 110,000 | $275.88 |
| 20 | 2020 - Q2 (2020-06-30) | $39,918,000 | 4.31% | 137,500 | $271.12 |
| 21 | 2020 - Q1 (2020-03-31) | $27,364,000 | 3.83% | 115,000 | $229.39 |
| 22 | 2019 - Q4 (2019-12-31) | $35,032,000 | 3.83% | 160,000 | $202.38 |
| 23 | 2019 - Q3 (2019-09-30) | $31,512,000 | 3.95% | 186,000 | $176.91 |
| 24 | 2019 - Q2 (2019-06-30) | $33,968,000 | 3.74% | 185,232 | $174.82 |
| 25 | 2018 - Q4 (2018-12-31) | $21,944,000 | 2.5% | 132,425 | $173.27 |
| 26 | 2018 - Q3 (2018-09-30) | $27,459,000 | 2.75% | 142,465 | $178.07 |
| 27 | 2018 - Q2 (2018-06-30) | $26,344,000 | 2.69% | 155,000 | $155.01 |
| 28 | 2018 - Q1 (2018-03-31) | $24,447,000 | 3.01% | 150,000 | $163.34 |
| 29 | 2017 - Q4 (2017-12-31) | $22,809,000 | 3.08% | 152,204 | $148.07 |
| 30 | 2017 - Q3 (2017-09-30) | $27,367,000 | 3.49% | 180,000 | $150.51 |
| 31 | 2017 - Q2 (2017-06-30) | $12,244,000 | 1.75% | 95,013 | $120.38 |
| 32 | 2017 - Q1 (2017-03-31) | $10,390,000 | 1.64% | 95,013 | $88.04 |
| 33 | 2016 - Q4 (2016-12-31) | $4,790,000 | 0.91% | 65,013 | $81.37 |
| 34 | 2016 - Q3 (2016-09-30) | $6,977,934,000 | 1.1% | 80,013 | $94.50 |
| 35 | 2016 - Q2 (2016-06-30) | $5,161,000 | 0.91% | 60,000 | $86.41 |
| 36 | 2016 - Q1 (2016-03-31) | $6,200,000 | 1.23% | 78,000 | $90.45 |
| 37 | 2015 - Q4 (2015-12-31) | $7,046,000 | 1.06% | 56,000 | $120.72 |
The displayed share prices are average quarterly stock market prices.